Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Conceptus, Inc.
Plaintiffs in a lawsuit alleging Bayer’s Essure contraceptive device caused patient injuries filed a revised complaint in California state courts this week. The coordinated proceedings include at least 3,000 patients, though no court date has yet been sent.
US FDA has accepted a post-approval study plan by Bayer HealthCare for its Essure permanent sterilization device, which is under intense scrutiny in response to adverse events and charges of clinical trial misconduct. The protocol entails a non-randomized, six-year cohort study comparing Essure-implanted women to tubal ligation sterilization subjects.
FDA is seeking industry representatives for device advisory panels; Smith & Nephew CEO begins cancer treatment; and news from TherOX, RAPS and Varian Medical Systems.
FDA will publicly announce actions it will take on Bayer’s Essure permanent birth control device at the end of February 2016 following its full review of the medical literature, adverse events reports, and input received during and after a September 24 advisory panel meeting on Essure, the agency said in a posting on its website.